
H5N1 bird flu virus is stable and infectious in raw milk cheese for months, study shows
Raw cheese made with milk from dairy cattle infected with bird flu can harbor infectious virus for months and may be a risk to public health, according to a new study from researchers at Cornell University that was funded by the US Food and Drug Administration.
Raw milk cheeses are those made with milk that hasn't been heat-treated, or pasteurized, to kill germs.
Although federal law prohibits the sale of raw milk across state lines, sales of raw milk cheese are legal nationwide as long as it's aged at least 60 days before landing on store shelves. This requirement, which has been in place since 1949, is thought to cut the risk of contamination, since it allows development of natural acids and enzymes, which were believed to kill off pathogens.
The new study shows that this aging process may not inactivate the H5N1 virus, however, and it underscores the risk of consuming raw or undercooked foods during the bird flu outbreak, which continues to infect dairy cattle, poultry and a growing number of other animal species.
The same group of researchers previously found that H5N1 virus remained infectious in refrigerated raw milk for up to eight weeks.
Dr. Diego Diel, who led the study, says he thinks the virus may be so stable in milk and cheese because it's protected by the complex matrix of molecules around it.
'The protein and fat content in the cheese and milk provide a good environment for the virus to survive at refrigeration temperature,' said Diel, an associate professor of virology at Cornell.
Robert F. Kennedy Jr., secretary of the US Department of Health and Human Services, has said food doesn't pose a bird flu risk.
'The disease is not passed through food, so you cannot get it – as far as we know, you cannot get it from an egg or milk or meat from an infected animal,' Kennedy told Fox News in an interview that aired Tuesday.
But that's only partly true. Cats and other animals have been infected by raw cow's milk and raw pet food, and there have been at least three confirmed human infections in which investigators were unable to determine the source of the person's exposure to the H5N1 virus.
There have been no confirmed reports of people getting sick from eating or drinking bird-flu contaminated foods, including raw milk cheese, but dairy workers have been infected by getting splashed with raw milk in their faces or eyes.
It's still not entirely clear whether humans can be infected by eating or drinking contaminated food, Diel said, noting that his study wasn't really designed to answer that question.
'I do think it is possible. There is a risk of infection,' he said. 'It obviously depends on the dose, how much of that contaminated product is ingested.'
It may also depend on the strain of virus in the milk or cheese. Diel and his team tested the stability of the B3.13 virus, which originally infected cattle in the US in March 2024. B3.13 has caused only mild disease in people. However, a new strain, D1.1, which has been associated with some severe human cases, has also crossed into cattle, further increasing the risk.
For the study, the researchers made mini cheeses with milk they spiked with H5N1 virus. They made these cheeses at three pH levels: 6.6, 5.8 and the most acidic formula, 5.0.
The researchers then tested the cheeses over time to see whether any virus capable of infecting cells remained. They injected samples into fertilized chicken eggs, considered the gold standard test.
Levels of the virus remained high for the first seven days after the cheese was made and then dropped a bit in the cheeses produced at pH levels 6.6 and 5.8. But importantly, the virus remained infectious for the full two-month aging period, showing that it was remarkably stable in the cheese over a long period.
Those results were confirmed by some real-world examples. The researchers tested samples of raw milk cheese from a farm that had inadvertently produced them with milk from cows infected with bird flu. These findings also showed that levels of virus stayed high and remained infectious over the full two months of aging.
'Our study demonstrates that HPAI H5N1 virus exhibits remarkable stability throughout the cheese making process,' the authors wrote in their preprint study, posted ahead of peer review Friday.
However, the study suggested that making raw milk cheese more acidic may kill the virus and make the cheese safer to eat. No live virus was detected in the cheese produced at the lowest pH, 5.0. Prior studies have also shown that common pasteurization methods inactivate the virus.
Experts said the new study was consistent with tests of the stability of the virus in milk.
'We have also observed that milk can change the pH needed to inactivate the virus,' said Dr. Seema Lakdawala, an associate professor of microbiology and immunology at Emory University, who has been studying the transmission of H5N1.
'We and others have repeatedly observed that milk will prevent the degradation of the virus on surfaces, and it increases the pH stability, such that a much lower pH than normal is needed to inactivate the virus,' said Lakdawala, who was not involved in the new study.
The FDA posted the findings of the study Friday along with preliminary results from its own ongoing sampling study of raw cheese.
The FDA sampling study, which was announced in December, has tested 110 cheese samples taken from store shelves across the country. So far, 96 of those samples were negative by polymerase chain reaction testing, or PCR, which detects live virus as well as inactive viral particles, indicating that those cheeses probably weren't made with contaminated milk. The results from the remaining 14 samples are pending, the agency said.
'The FDA is continuing to work with Federal and state partners to address the ongoing outbreak of HPAI A (H5N1) in dairy cattle. The FDA has sampled a total of 464 pasteurized dairy products, including milk cheese butter and ice cream, all were negative for viable H5N1. In addition, multiple research studies have confirmed that pasteurization inactivates the virus,' the statement said.
Still, experts say the study is a good reminder of the importance of surveillance – and of not consuming raw milk products.
'This is another reason we should push to ensure there is no bird flu in milk products and only consume pasteurized dairy products,' Lakdawala said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CDC: Bird flu virus that infected Michigan dairy farmer capable of airborne transmission
The strain of bird flu that infected a Michigan dairy farmworker is capable of airborne transmission, amping up concerns about its potential to spark a new pandemic, according to a research letter published in June. In recent years, the H5N1 avian influenza virus has spilled over from birds to a growing number of mammals, including cats, skunks, raccoons, oppossums, rodents and bears. It was first identified in dairy cows in 2024, and then leaped from cows to humans. In May 2024, two Michigan dairy farmworkers contracted the virus. The first reported conjuctivitis, also known as pink eye, as the only symptom. The second Michigan farmworker's symptoms were a little bit different. That person reported upper respiratory tract symptoms, including cough without fever, and eye discomfort with watery discharge. Both recovered. Researchers isolated the virus from a swab used to collect a sample from the eye of one of the infected workers. That virus — clade 2.3.4.4b, genotype B3.13 — was studied to determine how transmissible it is, and the ways it spreads. "Because avian H5N1 viruses cross the species barrier and adapt to dairy cattle, each associated human infection presents further opportunity for mammal adaption," the study authors wrote in "Emerging Diseases," a peer-reviewed journal of the U.S. Centers for Disease Control and Prevention. "This potential poses an ongoing threat to public health and requires continual surveillance and risk assessment ... to improve our ability to predict and prepare for the next influenza pandemic." Scientists infected ferrets with that type of virus. Six of the infected ferrets were put in the same living space as six healthy ferrets, and within a week, all of them had bird flu, showing that direct contact spreads the disease. Six other healthy ferrets had no direct contact with the infected animals, but were breathing the same air as ferrets with H5N1 bird flu, and inhaled respiratory droplets. Three of those six previously healthy ferrets became infected, the study found, suggesting an airborne infection rate of 50%. Researchers also collected aerosol samples daily from three infected ferrets, and found evidence of airborne virus particles in samples from all three animals. More: Michigan farmers call for H5N1 bird flu vaccines to protect flocks, dairy cows from virus Ferrets have been used for decades in medical research studies, especially those involving flu viruses, because their lung physiology is similar to humans. They also have similar receptors in the respiratory tract that influenza viruses bind to. All of the infected ferrets survived the 21-day study, researchers said, recovering from moderate disease. On average, ferrets infected with H5N1 bird flu lost nearly 10% of their body weight and had fevers. They were lethargic, and had nasal and ocular discharge along with sneezing. Since 2022, there have been 70 confirmed and probable human cases of bird flu in the U.S. One person in Louisiana, who was exposed to wild birds and a backyard flock, died. To date, there have been no reports of human-to-human transmission, according to the CDC. More: Michigan geese, angry owner change protocol for killing flock exposed to bird flu The CDC says the risk to the average American from bird flu remains low, but it's higher for people who work with animals on farms, at zoos and other animal facilities. Contact Kristen Shamus at kshamus@ Subscribe to the Detroit Free Press. This article originally appeared on Detroit Free Press: Virus that infected Michigan dairy farmer capable of airborne spread
Yahoo
2 hours ago
- Yahoo
Bird flu cases detected in seagulls in Cumbrian town
BIRD flu has been detected in a West Cumbrian town. Whitehaven Harbour Commissioners have confirmed that bird flu cases have been confirmed in the town. It is reported that the cases are affecting seagulls at the harbour. People are warned to take precautions when visiting the area, especially if walking a dog around the harbour. A Whitehaven Harbour Commissioners spokesman said: "Positive cases of avian influenza (bird flu) have been reported in the Whitehaven Harbour area. "There's no need to panic, but we kindly ask everyone to follow DEFRA's safety advice." Members of the public are urged to keep dogs on the lead at all times; do not touch wild birds; do not feed the birds; and wash your hands thoroughly if you come into contact with birds or droppings. Whitehaven Harbour Commissioners added: "We know it can be upsetting to see sick or injured birds but please do not approach or handle them. "For birds found on the Harbour, contact our office at 01946 590515 – a team member will help, or you can leave a message. "For birds in the water, please call Whitehaven Marina at 01946 692435. Thanks for helping keep our wildlife and community safe." The NHS says that bird flu, or avian flu, is an infectious type of influenza that spreads among birds. In rare cases, it can affect humans. There are lots of different strains of the bird flu virus. Most of them don't infect humans. The NHS website states: "Plans are in place to manage any suspected cases of bird flu in the UK. "H5N8 and H5N1 bird flu have been found in some poultry, other captive birds and wild birds in the UK. "H5N6 has also been found in some wild birds in the UK, but this is a different strain to the H5N6 virus that has infected some people in China."
Yahoo
6 hours ago
- Yahoo
DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.
HIGHLIGHTS Topline data from Clarity's diagnostic Phase II trial, DISCO, confirms that 64Cu-SARTATE is safe and highly effective compared to standard-of-care (SOC) imaging at detecting lesions in patients with neuroendocrine tumours (NETs). DISCO compared the diagnostic performance of 64Cu-SARTATE at an average of 4 hours (between 3 to 5 hours) and 20 hours post-administration (same-day and next-day imaging, respectively) to 68Ga-DOTATATE. 64Cu-SARTATE lesion detection substantially outperformed that of 68Ga-DOTATATE. 64Cu-SARTATE detected 393 to 488 lesions, and 68Ga-DOTATATE identified 186 to 265 lesions among 45 study participants across the readers. Out of all the lesions identified by the readers, 230-251 were deemed to be discordant (i.e. only present on one of the scans, 68Ga-DOTATATE or 64Cu-SARTATE positron emission tomography [PET] / computed tomography [CT]). Of these lesions, 93.5% (average across readers) were only detected on the 64Cu-SARTATE PET/CT scans. The number of discordant lesions detected by 64Cu-SARTATE on the same-day and next-day scans was comparable. Approximately half of all the discordant lesions had an available standard-of-truth (SOT), such as histopathology or conventional imaging. The identified discordant lesions yielded a lesion-level sensitivity of 93.4% to 95.6% (95% confidence interval [CI]: 65.1, 99.5) for 64Cu-SARTATE (across both timepoints) and only 4.4% to 6.6% (95%CI: 0.5, 34.9) for 68Ga-DOTATATE across both readers. 64Cu-SARTATE was deemed safe and well tolerated. Only 7 (15.6%) participants experienced 64Cu-SARTATE-related adverse events (AEs). No serious treatment-emergent AEs were observed in the study. Based on the exciting preliminary results of the DISCO trial, Clarity will commence next steps to conduct a registrational Phase III study of 64Cu-SARTATE in NETs with the US Food and Drug Administration's (FDA) guidance. SYDNEY, June 5, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce positive results from the diagnostic Phase II DISCO trial (NCT04438304)[1] with 64Cu-SARTATE in patients with known or suspected NETs. DISCO trial design DISCO is a "Diagnostic Imaging Study of 64COpper-SARTATE Using PET on Patients with Known or Suspected Neuroendocrine Tumours". It assessed the performance of Clarity's SARTATE imaging product as a potential new method to diagnose and manage NETs. The trial aimed to build on earlier clinical experience with 64Cu-SARTATE in patients with NETs, which demonstrated that the diagnostic has excellent imaging characteristics and suggested that 64Cu-SARTATE PET/CT provides comparable or superior lesion detection to 68Ga-DOTATATE PET/CT in all patients, especially in the liver[2]. DISCO recruited participants with Gastroenteropancreatic NETs (GEP-NETs) across 4 sites in Australia, comparing the diagnostic performance of 64Cu-SARTATE PET at an average of 4 hours (between 3 and 5 hours) and approximately 20 hours post-administration (same-day and next-day imaging, respectively) to the current SOC, 68Ga-DOTATATE PET. Participants were required to have undergone a pre-study 68Ga-DOTATATE PET/CT scan within 5 weeks, but not closer than 6 hours prior to the administration of 64Cu-SARTATE as part of their routine clinical care. The trial was initially designed to enrol up to 63 patients, based on the anticipated lesion-level discordance rate between 64Cu-SARTATE and 68Ga-DOTATATE PET. Following a pre-planned early analysis of the data collected during the study, the sample size was adjusted to 45 patients, allowing for an earlier enrolment completion. Study participants were dosed with 200 MBq of 64Cu-SARTATE. Both the 64Cu-SARTATE and 68Ga-DOTATATE PET/CT scans were reviewed by 2 blinded central readers. Participants were followed for up to 12 months to complete additional investigations (e.g. biopsy and conventional imaging) and obtain the SOT used to verify discordant findings between the scan pairs. The verification of discordant findings against the SOT evidence (as true- or false-positive findings) was completed by an independent central assessor, distinct from the central readers evaluating the 64Cu-SARTATE and 68Ga-DOTATATE scans. Lesion-level sensitivity was calculated for the discordant lesions between the scan pairs, with each true-positive discordant lesion on one scan considered a false-negative lesion on the other scan, and each false-positive discordant lesion on one scan considered a true-negative lesion on the other scan. Topline results The results indicate that lesion detection by 64Cu-SARTATE (regardless of imaging timepoint) substantially outperformed that of 68Ga-DOTATATE. 64Cu-SARTATE detected 393 to 488 lesions, and 68Ga-DOTATATE identified 186 to 265 lesions among 45 participants across the readers (Figure 1). Out of all lesions identified by the readers, 230-251 were deemed to be discordant between 64Cu-SARTATE and 68Ga-DOTATATE PET/CT, with 93.5% (average across readers and imaging days) of these discordant lesions detected on the 64Cu-SARTATE scans only. A previously completed Phase I study demonstrated a 1.7 fold increase (median of 6.70 vs. 3.92, p=0.002) in contrast (i.e. lesion-to-background ratio) for 64Cu-SARTATE PET/CT performed at 4 hours post-administration compared to 68Ga-DOTATATE PET/CT2. This improvement in contrast may explain the detection of additional lesions observed in the DISCO trial. The average SUVmax, representing the highest concentration of 64Cu-SARTATE uptake in lesions, was notably high, ranging from 37.42 to 43.90 across both imaging days in the DISCO trial. Approximately half of all discordant lesions had an available SOT, which yielded a lesion-level sensitivity of 93.4% to 95.6% (95%CI: 65.1, 99.5) for 64Cu-SARTATE, including both timepoints, and only 4.4% to 6.6% (95%CI: 0.5, 34.9) for 68Ga-DOTATATE. 64Cu-SARTATE was deemed safe and well tolerated. Only 7 (15.6%) trial participants experienced 64Cu-SARTATE-related AEs, the majority of which were mild (Grade 1) gastrointestinal events, commonly observed in NET patients, and typically resolved within 2 days of onset. No serious treatment-emergent AEs were observed in the study. Based on the findings of the DISCO trial to date, Clarity will commence the next steps to conduct a registrational Phase III study of 64Cu-SARTATE in NETs with the US FDA's guidance. Clarity's Executive Chairperson, Dr Alan Taylor, commented, "We are very excited about the initial topline data from the DISCO trial as 64Cu-SARTATE was confirmed to be safe and very effective in detecting NET lesions in patients with known or suspected disease. The DISCO trial demonstrates a significant advantage of our diagnostic over 68Ga-DOTATATE. 64Cu-SARTATE detected almost double the number of lesions compared to the SOC, and, where SOT was available, a very high lesion-level sensitivity of 93.4% - 95.6% in comparison to just 4.4% - 6.6% for 68Ga-DOTATATE for these discordant findings. In addition to identifying more lesions with our product, lesions detected by 64Cu-SARTATE also exhibited high uptake with low background on the PET scans, making it easier to identify those lesions by readers. Excellent lesion visualisation was also supported by substantial clearance from the liver. The favourable biodistribution of 64Cu-SARTATE PET enabled high-contrast diagnostic imaging for up to approximately 24 hours post-injection (Figure 1), offering greater flexibility in the scheduling of PET/CT scans. "In the DISCO trial, we continue to observe the substantial limitations of the current-generation of short half-life isotope products, what we call isotope-centric medicine. This is clearly illustrated by 68Ga-DOTATATE with imaging timepoints solely dictated by the very short isotope half-life (approximately 1 hour for gallium-68) as opposed to good science and medicine. In contrast, 64Cu-SARTATE highlights the extraordinary benefits of next-generation patient-centric medicine, where imaging is guided by the optimal timepoint to scan and detect lesions, focusing on the needs of the patients and their treating professionals. "We believe that the flexibility of imaging with 64Cu-SARTATE, in comparison to approximately 1 hour with 68Ga-DOTATATE, plays an important role in the detection benefits seen in the DISCO study. We have known this for many years and have demonstrated these advantages of optimal timepoint imaging with different products in our Targeted Copper Theranostic (TCT) platform, including SARTATE. We have seen first-hand in a number of clinical trials that once radiopharmaceutical products are administered, they take time to find the lesion whilst also needing to clear from non-target organs, providing greater contrast. This is known as signal-to-noise ratio or, in our case, tumour-to-background ratio. Having greater contrast is especially important to identify smaller or more difficult to find cancers. "The longer half-life of copper-64, combined with Clarity's proprietary SAR Technology, sets up a strong foundation for next-generation diagnostics, which could be unmatched in the radiopharmaceutical sector. In addition to clinical benefits, the opportunity for high-volume centralised manufacturing and broad, on-demand distribution of ready-to-use diagnostics translates into flexibility and reliability for patients and their treating staff, meaning that every patient with access to PET imaging, including those in underserved and broad geographic areas, may access improved cancer diagnostics. "Patients with NETs are often misdiagnosed and experience delays in receiving the correct diagnosis, which may lead to disease progression and identification of their cancer at later stages. Visualising NET lesions earlier and more accurately may have a significant impact on patient outcomes as it equips clinicians with crucial information on disease burden, helping to determine an optimal treatment plan. As such, the SSTR2 imaging market is an important focus for Clarity. We estimate the NET diagnostic market in the US alone to be around 100,000 scans per year, growing to approximately 120,000 scans per year by 2029. "Importantly, the positive results of the DISCO trial open broader opportunities for the development of 64Cu-SARTATE in additional SSTR2-expressing malignancies beyond NETs, such as certain types of breast and lung cancers, where unmet clinical needs remain high. We believe the SSTR2 market is set to grow substantially with a number of therapies in development for this target, which include large indications such as breast and lung cancers. Subject to the successful completion of these studies, we believe that the imaging market for 64Cu-SARTATE could be as large, if not larger, than the very lucrative prostate cancer imaging market where radiopharmaceuticals currently dominate the diagnostic paradigm. "We look forward to sharing additional data readouts from the trial and presenting the results at future international medical conferences. We plan to rapidly progress discussions with the FDA to initiate a diagnostic registrational Phase III study, as a first key step in expanding SARTATE into the theranostic field of NETs, as well as other SSTR2-expressing cancers, with the copper-64/copper-67 pair. If the findings from the DISCO trial are substantiated in a registrational Phase III study and lead to regulatory approval by the US FDA, 64Cu-SARTATE may play an important role in improving diagnostic accuracy, lesion detection and staging of patients with NETs. These factors could improve clinical decision-making and treatment outcomes, potentially positioning 64Cu-SARTATE as a best-in-class agent for the diagnosis of NETs." About SARTATE SARTATE is a next generation, highly targeted theranostic radiopharmaceutical. It is being developed for diagnosing, staging and subsequently treating cancers that express SSTR2, such as NETs. Like all Clarity products, the SARTATE product can be used with copper-64 (64Cu) for imaging (64Cu-SARTATE) or copper-67 (67Cu) for therapy (67Cu-SARTATE). Disclaimer 64Cu-SARTATE is an unregistered product. The safety and efficacy of 64Cu-SARTATE has not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that this product will become commercially available. About NETs NETs, also known as well-differentiated neuroendocrine neoplasms or carcinoids, represent a heterogeneous group of malignant transformations of cells of the diffuse neuroendocrine system[3]. They most commonly occur in the gastrointestinal tract (48%), lung (25%), and pancreas (9%), but may also originate in other areas, including the breast, prostate, thymus and skin[4]. NETs can either be benign or malignant, as well as non-functional and functional[5]. NETs traditionally have been considered uncommon; however, the incidence has been increasing as a worldwide phenomenon[6]. Overall, it is estimated that more than 20,000 people in the United States are diagnosed with a NET each year[7], and approximately 190,000 people are living with this diagnosis[8]. Patients with NETs present with subtle clinical symptoms, which can lead to a delay in diagnosis of more than 4 years[9]. As such, about 30-75% of NET patients have distant metastases at the time of diagnosis[10]. A 10-year relative survival rate for patients with metastatic GEP-NETs is 3–36%[11]. About Clarity Pharmaceuticals Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers. For more information, please contact: Clarity Pharmaceuticals Dr Alan Taylor Lisa SadetskayaExecutive Chairperson Director, Corporate Communicationsataylor@ lisa@ References [1] Identifier: NCT04438304 [2] Hicks R et al. First-in-human trial of 64Cu-SARTATE PET imaging of patients with neuroendocrine tumours demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. The Journal of Nuclear Medicine. 2019. [3] Cheung VTF, Khan MS. A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome. Frontline gastroenterology. 2015;6(4):264-269. [4] Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589-597. [5] Yau H, Kinaan M, Quinn SL, Moraitis AG. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. Biologics : targets & therapy. 2017;11:115-122. [6] Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017 Nov;58(2):368-379. doi: 10.1007/s12020-017 1273-x. Epub 2017 Mar 16. PMID: 28303513; PMCID: PMC5671554. [7] Wu C, Song Z, Balachandra S, Dream S, Chen H, Rose JB, Bhatia S, Gillis A. Charting the Course: Insights into Neuroendocrine Tumor Dynamics in the United States. Ann Surg. 2025 Jun 1;281(6):968-975. doi: 10.1097/SLA.0000000000006331. Epub 2024 May 6. PMID: 38708616; PMCID: PMC11538379. [8] Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589. PMID: 28448665; PMCID: PMC5824320. [9] Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer. 2018 Nov 16;18(1):1122. doi: 10.1186/s12885-018-5057-3. PMID: 30445941; PMCID: PMC6240263. [10] Aluri V. and Dillion, J.S. 2017, "Biochemical Testing in Neuroendocrine Tumors", Endocrinology & Metabolism Clinics of North America, [11] Polee, I.N. et al. 2022, "Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study", European Journal of Cancer, Volume 172, 2022, Pages 252-263, ISSN 0959-8049, • Krasnovskaya et al. Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals. Int J Mol Sci. 2023 May 23;24(11):9154. doi: 10.3390/ijms24119154. This announcement has been authorised for release by the Executive Chairperson. View original content to download multimedia: SOURCE Clarity Pharmaceuticals Sign in to access your portfolio